Context Therapeutics Inc.

NasdaqCM:CNTX Stock Report

Market Cap: US$20.3m

Context Therapeutics Dividend

Dividend criteria checks 0/6

Context Therapeutics no tiene antecedentes de pago de dividendos.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.3%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$1.50
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Mar 27
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely

Sep 28
Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely

Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?

Jun 05
Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?

Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24

Sep 27

We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Sep 15
We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Context Therapeutics GAAP EPS of -$0.25 in-line

Aug 11

Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial

Aug 02

Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

May 28
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential

Nov 02

Stability and Growth of Payments

Fetching dividends data

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de CNTX han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de CNTX han aumentado.


Dividend Yield vs Market

Context Therapeutics Dividend Yield vs Market
How does CNTX dividend yield compare to the market?
SegmentDividend Yield
Company (CNTX)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.3%
Analyst forecast in 3 Years (CNTX)n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de CNTX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de CNTX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.


Earnings Payout to Shareholders

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de CNTX para determinar si sus dividendos están cubiertos por los beneficios.


Cash Payout to Shareholders

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que CNTX no ha comunicado ningún pago.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.